Provista Life Sciences completes breast cancer trials

The BT Test is being made available to a select number of physicians in the Phoenix market as part of the company’s initial market release. The BT (biomarker translation) test is designed to assist physicians in making an earlier and more accurate diagnosis of breast cancer when used adjunctively with a mammogram.

William Gartner, Provista Life Sciences CEO, said: “Now that we’ve successfully completed our clinical trials, we are making the BT test available to a select group of local physicians in order to optimize the integration processes for physicians prescribing and administering the test. Our goal is to help save more women’s lives from this devastating disease. Once this initial process evaluation is complete, we expect to make the BT Test available throughout the entire Phoenix market, and expanding its availability to additional markets as lab capacity allows.”